Clinical Trials
29
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (29 trials with phase data)• Click on a phase to view related trials
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Opthea Limited
- Target Recruit Count
- 986
- Registration Number
- NCT04757610
- Locations
- 🇬🇧
ShORe Investigational Site, London, United Kingdom
🇧🇷ShORe Investigational site, Blumenau, Santa Catarina, Brazil
🇺🇸ShORe Investiagtional Site, Poway, California, United States
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Biological: 2.0 mg OPT-302Biological: 2.0 afliberceptProcedure: Sham
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Opthea Limited
- Target Recruit Count
- 998
- Registration Number
- NCT04757636
- Locations
- 🇬🇧
COAST Investigational Site, London, United Kingdom
🇺🇸COAST Investigational site, Shirley, New York, United States
A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Opthea Limited
- Target Recruit Count
- 153
- Registration Number
- NCT03397264
- Locations
- 🇱🇻
Opthea Investigational Site, Riga, Latvia
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
- Conditions
- Neovascular Age-related Macular Degeneration
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Opthea Limited
- Target Recruit Count
- 366
- Registration Number
- NCT03345082
- Locations
- 🇬🇧
Opthea Investigational Site, Wolverhampton, United Kingdom
🇺🇸Opthea Study Site, Sacramento, California, United States
🇵🇱Opthea Investigationa Site, Lublin, Poland
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
- Conditions
- Eye DiseasesMacular DegenerationRetinal DiseasesRetinal DegenerationNeovascularization, Pathologic
- Interventions
- Drug: Lucentis™
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Opthea Limited
- Target Recruit Count
- 51
- Registration Number
- NCT02543229
- Locations
- 🇺🇸
Opthea Investigative Site, Willow Park, Texas, United States
News
Sozinibercept Shows Promise in Wet AMD Treatment as Opthea's Pivotal Trials Progress
Opthea's sozinibercept (OPT-302) demonstrates potential to enhance visual outcomes in wet age-related macular degeneration patients without competing with standard anti-VEGF-A therapies.